DFO
LUMO

Duquesne Family Office’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Duquesne Family Office’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-20,278
Closed -$3.91M – 48
2014
Q3 		$3.91M Buy
+20,278
New +$4.46M 0.48% 34

Other funds holding LUMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Duquesne Family Office's LUMO Position: Q4 2014 in Review

Duquesne Family Office sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2014, closing a stake of 20,278 shares — an estimated $3.91M sold.

Duquesne Family Office first reported a position in LUMO in Q3 2014 and held it in 1 quarter. The position peaked at $3.91M in Q3 2014. 100 funds tracked by Wall St. Rank hold LUMO as of Q4 2014.

  • Duquesne Family Office reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Duquesne Family Office sold 20,278 Lumos Pharma, Inc. Common Stock shares in Q4 2014, an estimated $3.91M.
  • Duquesne Family Office first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2014 and held it in 1 quarter.
  • Duquesne Family Office's Lumos Pharma, Inc. Common Stock position peaked at $3.91M in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2014.

Based on Duquesne Family Office's 13F filing for Q4 2014, filed 12 Feb 2015.